ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $28.80 Average Price Target from Brokerages
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target […]
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target […]
